(S)-2-(3-bromo-4-((6-methoxy-2-phenylpyrimidin-4-yl)oxy)phenyl)-2-((tertbutoxycarbonyl)amino)acetic acid | 1450789-65-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (S)-2-(3-bromo-4-((6-methoxy-2-phenylpyrimidin-4-yl)oxy)phenyl)-2-((tertbutoxycarbonyl)amino)acetic acid
• CAS: 1450789-65-7
• 化学式: C₂₄H₂₄BrN₃O₆
• 分子量: 530.375
• InChiKey: YMQFYDFVNHQRDV-FQEVSTJZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.36
• 重原子数：
  34.0
• 可旋转键数：
  7.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  119.87
• 氢给体数：
  2.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  (S)-2-(3-bromo-4-((6-methoxy-2-phenylpyrimidin-4-yl)oxy)phenyl)-2-((tertbutoxycarbonyl)amino)acetic acid 在 palladium diacetate 、 potassium carbonate 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 tri tert-butylphosphoniumtetrafluoroborate 作用下， 以 乙二醇二甲醚 、 二氯甲烷 、 水 为溶剂， 反应 3.25h， 生成 tert-butyl (1-(4-((6-methoxy-2-phenylpyrimidin-4-yl)oxy)-3-vinylphenyl)-2-oxo-2-((3-(((4-(trifluoromethyl)phenyl)sulfonyl)carbamoyl)phenyl)amino)ethyl)carbamate
  参考文献：
  名称：

  Novel Peptidomimetic Hepatitis C Virus NS3/4A Protease Inhibitors Spanning the P2–P1′ Region

  摘要：

  Herein, novel hepatitis C virus NS3/4A protease inhibitors based on a P2 pyrimidinyloxyphenylglycine in combination with various regioisomers of an aryl acyl sulfonamide functionality in P1 are presented. The P1' 4-(trifluoromethyl)phenyl side chain was shown to be particularly beneficial in terms of inhibitory potency. Several inhibitors with K i-values in the nanomolar range were developed and included identification of promising P3-truncated inhibitors spanning from P2-P1'. Of several different P2 capping groups that were evaluated, a preference for the sterically congested Boc group was revealed. The inhibitors were found to retain inhibitory potencies for A156T, D168V, and R155K variants of the protease. Furthermore, in vitro pharmacokinetic profiling showed several beneficial effects on metabolic stability as well as on apparent intestinal permeability from both P3 truncation and the use of the P1' 4-(trifluoromethyl)phenyl side chain.

  DOI：

  10.1021/ml400217r
• 作为产物：
  描述：

  解草啶 在 potassium tert-butylate 作用下， 以 甲醇 、 二甲基亚砜 为溶剂， 反应 48.0h， 生成 (S)-2-(3-bromo-4-((6-methoxy-2-phenylpyrimidin-4-yl)oxy)phenyl)-2-((tertbutoxycarbonyl)amino)acetic acid
  参考文献：
  名称：

  Novel Peptidomimetic Hepatitis C Virus NS3/4A Protease Inhibitors Spanning the P2–P1′ Region

  摘要：

  Herein, novel hepatitis C virus NS3/4A protease inhibitors based on a P2 pyrimidinyloxyphenylglycine in combination with various regioisomers of an aryl acyl sulfonamide functionality in P1 are presented. The P1' 4-(trifluoromethyl)phenyl side chain was shown to be particularly beneficial in terms of inhibitory potency. Several inhibitors with K i-values in the nanomolar range were developed and included identification of promising P3-truncated inhibitors spanning from P2-P1'. Of several different P2 capping groups that were evaluated, a preference for the sterically congested Boc group was revealed. The inhibitors were found to retain inhibitory potencies for A156T, D168V, and R155K variants of the protease. Furthermore, in vitro pharmacokinetic profiling showed several beneficial effects on metabolic stability as well as on apparent intestinal permeability from both P3 truncation and the use of the P1' 4-(trifluoromethyl)phenyl side chain.

  DOI：

  10.1021/ml400217r

文献信息

• Vinylated linear P2 pyrimidinyloxyphenylglycine based inhibitors of the HCV NS3/4A protease and corresponding macrocycles
  作者：Anna Lampa、Hiba Alogheli、Angelica E. Ehrenberg、Eva Åkerblom、Richard Svensson、Per Artursson、U. Helena Danielson、Anders Karlén、Anja Sandström

  DOI：10.1016/j.bmc.2014.10.010

  日期：2014.12

  With three recent market approvals and several inhibitors in advanced stages of development, the hepatitis C virus (HCV) NS3/4A protease represents a successful target for antiviral therapy against hepatitis C. As a consequence of dealing with viral diseases in general, there are concerns related to the emergence of drug resistant strains which calls for development of inhibitors with an alternative binding-mode than the existing highly optimized ones. We have previously reported on the use of phenylglycine as an alternative P2 residue in HCV NS3/4A protease inhibitors. Herein, we present the synthesis, structure-activity relationships and in vitro pharmacokinetic characterization of a diverse series of linear and macrocyclic P2 pyrimidinyloxyphenylglycine based inhibitors. With access to vinyl substituents in P3, P2 and P1' positions an initial probing of macrocyclization between different positions, using ring-closing metathesis (RCM) could be performed, after addressing some synthetic challenges. Biochemical results from the wild type enzyme and drug resistant variants (e.g., R155 K) indicate that P3-P1' macrocyclization, leaving the P2 substituent in a flexible mode, is a promising approach. Additionally, the study demonstrates that phenylglycine based inhibitors benefit from p-phenylpyrimidinyloxy and m-vinyl groups as well as from the combination with an aromatic P1 motif with alkenylic P1' elongations. In fact, linear P2-P1' spanning intermediate compounds based on these fragments were found to display promising inhibitory potencies and drug like properties. (C) 2014 Elsevier Ltd. All rights reserved.